PT. RICHMOND, Calif., Dec. 1 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Glenn A. Oclassen, President & Chief Executive Officer, is scheduled to participate at the RBC Capital Markets 2008 Healthcare Conference in New York City on a panel entitled “Delivering Novel Drug Solutions: The Future of Drug Delivery.” This presentation is scheduled to take place on Thursday, December 11, 2008 at 1:30 PM Eastern Time.
An audio webcast of the presentation will be available at http://www.transcept.com. The replay of the presentation will be available for 30 days.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration.
For further information, please visit the company’s website at: http://www.transcept.com.
Safe Harbor
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Transcept disclaims any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected benefits of Transcept product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, Transcept product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA approval; physician or patient reluctance to use Intermezzo(R), if approved; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in, clinical development, obtaining regulatory approval, market acceptance and commercialization of Transcept product candidates.
CONTACT: Michael Gill, Director of Communications of Transcept
Pharmaceuticals, Inc., +1-510-215-3575, mgill@transcept.com; or Investors,
Stephanie Carrington, +1-646-536-7017, scarrington@theruthgroup.com, or
Media, Jason Rando, +1-646-536-7025, jrando@theruthgroup.com, both of The
Ruth Group, for Transcept Pharmaceuticals, Inc.
Web site: http://www.transcept.com/
